Dan Emil Lind
6PUBLICATIONS
28CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Aug 08, 2025
Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactions.Joachim T Siaw, Peter Merseburger, Marcus Borenäs
|Dec 28, 2023
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.Marcus Borenäs, Ganesh Umapathy, Dan E Lind
|Nov 25, 2021
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.Joanna Szydzik, Dan E Lind, Badrul Arefin
|Jan 07, 2021
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.Marcus Borenäs, Ganesh Umapathy, Wei-Yun Lai
|Dec 20, 2019
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.Diana Cervantes-Madrid, Joanna Szydzik, Dan Emil Lind
|Nov 30, 2017
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.Ganesh Umapathy, Jikui Guan, Dan E Gustafsson
Pageof 1
Frequent Collaborators
5 joint publications
Ruth H Palmer
5 joint publications
Bengt Hallberg
4 joint publications
Jimmy Van den Eynden
2 joint publications
Jikui Guan
2 joint publications
Arne Claeys
2 joint publications
Diana Cervantes-Madrid
2 joint publications
Mats Bemark
2 joint publications
Marcus Borenäs
2 joint publications
Joachim Tetteh Siaw
1 joint publications
Ganesh Umapathy
